PARP inhibitors are a type of targeted cancer drug. They are a treatment for some women with ovarian cancer. They are also in trials as a treatment for other types of cancer. Olaparib, niraparib and rucaparib are all examples of PARP inhibitors.
How do PARP inhibitors work?
PARP is a protein (enzyme) found in our cells, It helps damaged cells to repair themselves. As a cancer treatment, PARP inhibitors stop the PARP from doing its repair work in cancer cells and the cell dies. Researchers first looked at these drugs in cancers that already had problems repairing cell damage. They focused on cancers with a change (or fault) in genes called BRCA.
PARP inhibitor with PRRT clinical trials update. 1. NIH Trial SummaryA phase I/II clinical trial at the NIH Clinical Center evaluates the effectiveness of a combination of two agents that may work in complementary ways to target inoperable or metastatic neuroendocrine tumoors. One agent, lutathera, emits radiation inside the body, causing DNA damage, and the second agent, olaparib, a PARP inhibitor, blocks the repair of DNA breaks. The trial commences in Oct 2022 running for approximately 2 years 9 months. What is Lutathera?It's a type of Peptide Receptor Radionuclide Therapy (PRRT) and has been in use for some years as a standard of care (mostly second line). Read more click here.What is Olaparib and what does it do in conjunction with Lutathera?Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed…